Hemoglobinopathy Treatment Market to Witness Astonishing Growth by 2029
Hemoglobinopathy Treatment Market is anticipated to grow at a significant CAGR during the forecast period. The growth of the market is primarily attributed to a surge in the cases of hemoglobinopathies, as well as the public awareness of hemoglobin disorders. According to the World Health Organization, about 1.1% of the expecting parents globally are at the risk of having a child with hemoglobin disorder. Adding to this, a strong product pipeline aiming towards the treatment of hemoglobinopathies coupled with the constant endeavours from the market players and government in developing the new therapies for the treatment of hemoglobinopathies are projected to uplift the market.
Likewise, various government and
private organizations led initiatives such as neonatal screening to detect the
potential disorders are further projected to fuel the market growth. Along with
the governmental programs, rising approvals for novel therapies from the
regulatory bodies are expected to boost the market growth. For instance, in
2019, the FDA approved Reblozyl, Adakveo, Zynteglo, and Oxbryta for the
treatment of haemoglobin disorders.
Some key players operating in the market include
Sanofi S.A., Global Blood Therapeutics, Inc., bluebird bio, Inc., EMI Holding,
Inc., Celgene Corp. These players are eyeing to strengthen their position in
the market by adopting various strategies as mergers and acquisitions,
partnerships, collaborations, new product launch and development in the existing
product portfolio, and so on. For instance, in May 2017, Sangamo Therapeutics
and Pfizer announced a collaboration for haemophilia A gene therapy. Such
collaborations are further anticipated to drive market growth. Further, in
December 2017, CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated
entered into a partnership to develop and commercialize novel gene-editing
treatments for thalassemia using CRISPR/Cas9 technology.
To Request a Sample of our Report on Hemoglobinopathy
Treatment Market: https://www.omrglobal.com/request-sample/hemoglobinopathy-treatment-market
Market Coverage
·
The market number available for – 2020-2030
·
Base year- 2022
·
Forecast period- 2021-2030
·
Segment Covered
·
Regions Covered- Globally
Competitive Landscape: Sanofi S.A., Global Blood Therapeutics, Inc.,
bluebird bio, Inc., EMI Holding, Inc., Celgene Corp, among others.
A
full Report of Hemoglobinopathy Treatment Market is Available @ https://www.omrglobal.com/industry-reports/hemoglobinopathy-treatment-market
Hemoglobinopathy Treatment Market by Segment
By Treatment
•
Stem Cell Therapy
•
Blood Transfusion,
•
Iron Chelation Therapy,
•
Others
By Application
•
Thalassemia
•
Sickle Cell Anaemia
•
Others
Hemoglobinopathy Treatment Market by
Region
· United
States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest
of Europe
Asia-Pacific
· India
· China
· Japan
· South
Korea
· Rest
of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data,
Request for Report Customization @ https://www.omrglobal.com/report-customization/hemoglobinopathy-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and
consulting company known for its crisp and concise reports. The company is
equipped with an experienced team of analysts and consultants. OMR offers
quality syndicated research reports, customized research reports, consulting
and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and
Consulting Services through another subsidiary Encanto Technologies.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment